Skip to main content
PMI logo

Picard Medical, Inc. (PMI) Stock Price & Analysis

Picard Medical, Inc. (PMI) — MoonshotScore 23/100 (Weak band), calculated Nov 18, 2026. Price $6.79 (+7.78%), as of the Nov 20, 2026 trading session; market cap $18.1M.

Educational signal · not a buy or sell recommendation · How to read this

$6.79 +$0.49 (+7.78%) Market Cap $18.1M

Picard Medical, Inc. · PMI

Picard Medical, Inc. (PMI) specializes in the commercialization of medical devices, notably the SynCardia TAH, a total artificial heart.

Price as of Nov 20, 2026

Key Statistics

23 of 100

MoonshotScore v2 · Picard Medical (PMI)

Weak
Business Quality Poor (12)
Financial Safety Okay (58)
Valuation Bubble (9)
Growth Durability Flat (42)
Momentum Quiet (43)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality and an expensive valuation, though growth is only middling. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Okay; Valuation: Bubble; Growth Durability: Flat; Momentum: Quiet.

  • quarterly revenue $1M (Q3 FY2025, quarter ended Sep 2025)
  • Altman Z 37.76 · Piotroski F 3

Holding back: weak fundamentals, a rich price

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for PMI (58 recorded, newest six shown)
RecordedScoreBand
25Weak
25Weak
25Weak
23Weak
23Weak
23Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$6.79
Change on the day+7.78%
Market capitalisation$18.1M—
Shares traded on the day20.3K

Price & events

Other perspectives

Council score for Picard Medical (PMI): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Negative
Financial Safety Neutral
Valuation Negative
Growth Durability Neutral
Momentum Neutral

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Debt/Equity Negative
ROE Negative
Gross Margin Neutral

Read on: Nov 20, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Picard Medical (PMI), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Picard Medical, Inc. (PMI) is the company analyzed here. It employs 75 people. In Q3 FY2025 it reported revenue of $1M and net income of -$10M. The market values it at $18.1M.

2 · Latest results

What do the latest results show for Picard Medical (PMI)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $1M.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$1M-$10M-$9.57 (diluted)
Q4 FY2025$1M-$4M—
Q1 FY2026$1M-$8M-$5.12 (diluted)
Q2 FY2026$3M-$6M-$3.05 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Picard Medical (PMI)?

Short answer

What is holding it back is weak fundamentals, a rich price. The distress and quality screens read Altman Z 37.76 · Piotroski F 3. Trailing ratios: ROA -78.8% · current ratio 0.99.

5 · Peer comparison

How does Picard Medical compare with its peers?

Short answer

Picard Medical's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Electromed, Inc. (ELMD) Same industry, near in market value$22.98 Nov 20, 2026$188M87 5-pillar Nov 18, 2026
Medtronic plc (MDT) Named competitor$99.94 Nov 20, 2026$128B81 5-pillar Nov 18, 2026
Stryker Corporation (SYK) Named competitor$313.08 Nov 19, 2026$119B80 5-pillar Nov 18, 2026
Boston Scientific Corporation (BSX) Named competitor$41.98 Nov 20, 2026$60.9B77 5-pillar Nov 18, 2026
Anika Therapeutics, Inc. (ANIK) Same industry, near in market value$13.23 Nov 20, 2026$177M71 5-pillar Nov 18, 2026
Abbott Laboratories (ABT) Named competitor$103.00 Nov 20, 2026$178B69 5-pillar Nov 18, 2026
LENSAR, Inc. (LNSR) Same industry, near in market value$4.64 Nov 19, 2026$57.1M44 5-pillar Nov 18, 2026
Solana Company (HSDT) Same industry, near in market value$1.49 Nov 20, 2026$93.7M43 5-pillar Nov 18, 2026
Owlet, Inc. (OWLT) Same industry, near in market value$3.23 Nov 19, 2026$96.5M41 5-pillar Nov 18, 2026
Hyperion DeFi, Inc. (HYPD) Same industry, near in market value$2.08 Nov 20, 2026$31.7M39 5-pillar Nov 18, 2026
Inogen, Inc. (INGN) Same industry, near in market value$5.30 Nov 20, 2026$138M37 5-pillar Nov 18, 2026
Orthofix Medical Inc. (OFIX) Same industry, near in market value$6.07 Nov 20, 2026$247M36 5-pillar Nov 18, 2026
Picard Medical (PMI) — this page$6.79$18.1M23

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Insider activity

Form 4 records via FMP · Most recent available transactions

Transactions
12
Identified insiders
3
Purchases
0
Sales
0
Other transactions
12

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held PMI in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported PMI in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Picard Medical (PMI)?

Read these with our analysis →

Investor Questions: PMI Stock

These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.

What does the MoonshotScore mean for PMI?

PMI carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is PMI a good stock to buy?

Stock Expert AI does not rate PMI buy, sell or hold. Picard Medical, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the PMI stock price today?

The last price recorded for Picard Medical, Inc. (PMI), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the key factors to evaluate for PMI?

Picard Medical, Inc. (PMI) holds a MoonshotScore in the low range. Collaborations can lead to increased market access and shared resources, driving growth and innovation over the next few years. Not financial advice.

How frequently does PMI data refresh on this page?

PMI's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven PMI's recent stock price performance?

Picard Medical, Inc. (PMI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product offerings, particularly the SynCardia TAH. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider PMI overvalued or undervalued right now?

Picard Medical, Inc. (PMI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research PMI before investing?

Before investing in Picard Medical, Inc. (PMI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding PMI to a portfolio?

Key strength of Picard Medical, Inc. (PMI): Innovative product offerings, particularly the SynCardia TAH. Weigh rewards against risks and diversify. Not financial advice.

Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 13 figures on this page — 9 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.